Author Interviews, Gender Differences, Hepatitis - Liver Disease, Infections / 10.07.2020
Cost-Effectiveness of Routine Hepatitis C Testing
MedicalResearch.com Interview with:
[caption id="attachment_54838" align="alignleft" width="150"]
Dr. Assoumou[/caption]
Sabrina Annick Assoumou, MD, MPH
Assistant Professor, Medicine
Infectious Diseases at Boston Medical Center
Boston University School of Medicine
MedicalResearch.com: What is the background for this study?
Response: During the opioid epidemic there has been an increase in the number of hepatitis C virus (HCV) infections due to transmission among persons who inject drugs (PWID). Federally qualified health centers (FQHC) provide care to an underserved and diverse patient population with a high proportion of both injection drug use and HCV. These health care facilities could provide opportunities to enhance HCV testing and treatment, especially at a time when recent data show that the United States is not on the list of high-income nations expected to achieve the World Health Organization’s goal of eliminating HCV by 2030.
Dr. Assoumou[/caption]
Sabrina Annick Assoumou, MD, MPH
Assistant Professor, Medicine
Infectious Diseases at Boston Medical Center
Boston University School of Medicine
MedicalResearch.com: What is the background for this study?
Response: During the opioid epidemic there has been an increase in the number of hepatitis C virus (HCV) infections due to transmission among persons who inject drugs (PWID). Federally qualified health centers (FQHC) provide care to an underserved and diverse patient population with a high proportion of both injection drug use and HCV. These health care facilities could provide opportunities to enhance HCV testing and treatment, especially at a time when recent data show that the United States is not on the list of high-income nations expected to achieve the World Health Organization’s goal of eliminating HCV by 2030.
Dr. Dixon[/caption]
Cinnamon A. Dixon, DO, MPH
Associate Professor of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado
Senior Investigator | Center for Global Health
Colorado School of Public Health
Aurora, CO
MedicalResearch.com: What is the background for this commentary?
Response: Dog bites are a long-standing public health problem. Each year there are approximately 4.5 million dog bites across the Unites States (US),1 and global estimates suggest tens of millions of these injuries worldwide.2 Children are the most vulnerable population with nearly 1 million annual dog bites in the US and more severe injury outcomes.1
National organizations espouse consistent strategies on how to prevent dog bites to children, however studies reveal that most children have never received dog bite prevention education.3,4 Furthermore, children lack critical knowledge of how to prevent dog bites in high-risk “resource guarding” situations (such as when a dog is eating or chewing on toys).4
During the COVID-19 pandemic, millions of US households are experiencing restrictions in activities. Children now spend more time in the home environment and presumably have increased exposure to their pet dogs. Parents and caregivers likely experience greater stress with more potential for competing interests and resultant decreased supervision of their children and dogs. Finally, pet dogs may be affected by the increased tension of their environment and be more likely to mirror the emotions of their human caregivers.
We hypothesized that these combined elements compound the risk of dog bites to children during the COVID-19 pandemic.
Samia Arshad[/caption]
Samia Arshad, MPH
Epidemiologist II
Infectious Disease
Henry Ford Hospital, Detroit, MI
I would like to start off by saying: We need to keep partisanship out of science. During this pandemic, we hope we can stick to science and help save lives with purposeful data driven facts.
MedicalResearch.com: What is the background for this study?
Response: Hydroxychloroquine, an antimalarial and immunomodulatory agent has demonstrated antiviral activity against SARS-CoV-2. We are in an acceleration phase of the COVID-19 pandemic, with 25% of the world’s cases occurring in the United States. Currently there is no known therapy or vaccine for treatment of SARS-CoV-2, highlighting the urgency around identifying effective therapies. The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.
Dr. Kempe[/caption]
Allison Kempe, MD, MPH
Ergen Family Endowed Chair in Pediatric Outcomes Research
Professor of Pediatrics, University of Colorado School of Medicine
Director of ACCORDS (Adult and Child Consortium for Health Outcomes Research and Delivery Science)
University of Colorado School of Medicine | Children’s Hospital Colorado
MedicalResearch.com: What is the background for this study?
Response: In 2019 the WHO designated vaccine hesitancy as one of the ten leading threats to global health. Although studies have assessed parental vaccine hesitancy in different localities and estimated vaccine refusals nationally, there is little recent US national data on the prevalence of hesitancy about routine childhood vaccines and national hesitancy rates for influenza vaccine have never been assessed. We used a hesitancy scale developed by the WHO to estimate levels of parental hesitancy for both routine childhood and childhood influenza vaccination
Dr. Blume[/caption]
Dr. Christine Blume PhD
Centre for Chronobiology
Psychiatric Hospital of the University of Basel
Transfaculty Research Platform Molecular and Cognitive Neurosciences
Basel
MedicalResearch.com: What is the background for this study?
Response: In modern societies, human rest-activity rhythms and sleep are between the often-conflicting poles of external social time (e.g., work hours and leisure activities) and an individual’s internal biological time. This can lead to so-called “social jetlag”, which has repeatedly been associated with detrimental health effects. With the restrictions to control the pandemic, social timing relaxed as people many started working from home and public life came to a standstill. In an online survey with 435 respondents, we investigated the effects of the phase with the strictest COVID-19 restrictions on the relationship between social and biological rhythms as well as sleep during a six-week period (mid-March until end of April 2020) in three European societies (Austria, Germany, Switzerland).
Dr. Hooker[/caption]
Edmond A. Hooker, MD, DrPH
Professor, Department of Health Services Administration
MHSA Associate Director for Accreditation
Xavier University
Cincinnati, Ohio
MedicalResearch.com: What is the background for this study?
Response: Healthcare acquired infections are still a huge problem in the US. Most hospitals are not following the hospital bed manufacturers guidelines for cleaning these mattresses and bed decks (the metal bed frame). Many use only a single step, when the manufacturers recommend a 5-6 step process (pre-clean any obvious soil, clean, rinse off cleaner, disinfect, rinse off disinfectant, inspect mattress for damage). The problem is that, if done, this takes 45 minutes to 1 hours. Most hospitals turn over a hospital room in less than 30 minutes. The launderable bed cover allows the bed to be cleaned and turned over in minutes, not an hours.
Dr. Schünemann[/caption]
Holger Schünemann, MD, PhD, FRCPC
Professor of Clinical Epidemiology and of Medicine
Co-Director, WHO Collaborating Centre for Infectious Diseases,
Research Methods and Recommendations
Director, Cochrane Canada and McMaster GRADE Centre
Department of Health Research Methods, Evidence, and Impact
Canada
MedicalResearch.com: What is the background for this study?
Response: Many countries and regions have issued conflicting advice about physical distancing to reduce transmission of COVID-19, based on limited information. In addition, the questions of whether masks and eye coverings might reduce transmission of COVID-19 in the general population, and what the optimum use of masks in healthcare settings is, have been debated during the pandemic.
Dr. Van der Pol[/caption]
Barbara Van Der Pol, PhD, MPH
President, American STD Association
President-Elect, International Society fo STD Research
Professor of Medicine & Public Health
Director, STD Diagnostics Lab
Director, UAB STD Clinical Research Organization
University of Alabama at Birmingham
Birmingham, AL 35294
MedicalResearch.com: What is the background for this study?
Response: For many decades, public health programs focused on control and prevention of sexually transmitted infections (STI) have relied on lab based tests that required a 1-day to 1-week wait for test results. Efforts to shorten the duration of infection lead to treating at the time of the clinic visit based on the association between certain clinical signs or symptoms and the likelihood of infection.
Unfortunately, more than ½ of infected persons do not have signs or symptoms so they receive no treatment until test results are available. Thus, a test that could be performed at the clinical site with a limited wait time would improve the accuracy of treatment and shorten the duration of infection. Such a strategy will hopefully reduce the number of return clinic visits, the possibility of transmission, and the potential for consequences of untreated infection such as infertility.
Marco Taglietti, M.D.
President and Chief Executive Officer
SCYNEXIS Inc
Dr. Taglietti discusses SCYNEXIS’ announcement of positive results from its second Phase 3 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for vaginal yeast infection.
[caption id="attachment_54239" align="alignleft" width="200"]
Dr. Kaufman[/caption]
Gregory Kaufman, M.D.
Senior Vice President
Global Clinical and Medical Affairs
Specialty at Lupin
MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by trichomoniasis? How common is this infection?
Response: The Phase 3 trial evaluated the effectiveness and safety of a single oral dose of Solosec® (secnidazole) 2g oral granules for the treatment of trichomoniasis in adult women. Top-line results were positive and showed that Solosec was generally well-tolerated.
Trichomoniasis is the most common non-viral sexually transmitted infection (STI) in the U.S., and is caused by a protozoan parasite called Trichomonas vaginalis.